Tissue Regenix Group PLC Hardman & Co Research Report
January 25 2016 - 2:00AM
RNS Non-Regulatory
TIDMTRX
Tissue Regenix Group PLC
25 January 2016
Hardman & Co issues research report on Tissue Regenix Group
plc
From development - into the commercial world: Tissue Regenix is
no longer an R&D play. Its dCELL(R) technology allows for the
production of 'like-for-like' tissue specific, structure-preserving
scaffolds that have been validated in multiple clinical settings.
Following the US launch of DermaPure(R), we expect a series of
further product launches over the next two years in Orthopaedic
Sports Medicine and heart valve replacement, substantial markets
with significant unmet medical need. The Company continues to build
long term value despite short term monthly cashburn of () GBP0.8m.
An NPV of 42p is driven by three core product areas; the true value
of the platform and product streams has still to be elucidated.
Please click here for the full report:
http://www.hardmanandco.com/system/files/research_papers/TRX%20Initiation%20Note%20-%2025%20January%202016.pdf
To contact us: Contact: Dr Martin Hall
Hardman & Co mh@hardmanandco.com
11/12 Tokenhouse Telephone: +44 20 7929 3399
Yard Follow us on Twitter @HardmanandCo
London
EC2R 7AS
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPGUWPGUPQPGC
(END) Dow Jones Newswires
January 25, 2016 02:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Oct 2023 to Oct 2024